Immunohistochemical (IHC) Biomarkers: Key Tools for Gastric and Colorectal Cancer Diagnosis

Core Concepts

Tumor biomarkers serve as indispensable molecular indicators for early cancer screening, differential diagnosis, and prognostic evaluation. Immunohistochemistry (IHC) represents the gold-standard clinical technique for visualizing and quantifying these biomarkers in tissue samples, enabling precise localization and characterization of malignant lesions. When integrated with diagnostic imaging, IHC analysis empowers clinicians to determine tumor staging, histological classification, and optimal therapeutic strategies for personalized cancer care.

Research Frontiers in Gastrointestinal Cancer Biomarkers

The landscape of gastric and colorectal cancer research is rapidly evolving, with a strong emphasis on identifying highly specific and sensitive IHC biomarkers. These molecular targets not only facilitate accurate tumor diagnosis but also guide the development of targeted therapeutic agents, addressing the unmet clinical need for effective precision medicine in gastrointestinal malignancies. Recent scientific advances have highlighted several novel and established biomarkers with exceptional diagnostic and therapeutic potential.

Research Significance

Gastric and colorectal cancers are among the most prevalent and lethal malignancies worldwide, associated with high morbidity and mortality rates due to late-stage diagnosis and limited treatment options. IHC-based biomarker detection addresses critical clinical challenges by enabling early tumor identification, distinguishing between benign and malignant lesions, predicting patient prognosis, and selecting candidates for targeted therapy. This approach significantly improves clinical outcomes and quality of life for cancer patients.

Key Biomarker Mechanisms & Diagnostic Applications

Biomarkers for Gastric Cancer Diagnosis

1. Claudin 18.2

Claudin 18.2 is a specific isoform encoded by the CLDN18 gene, a member of the claudin protein family that maintains epithelial tight junction integrity. This biomarker is selectively overexpressed in gastric tumor tissues, playing a critical role in tumorigenesis, invasion, and metastasis. Located on the cell surface with accessible extracellular domains, Claudin 18.2 serves as a prime target for monoclonal antibody-based therapies and diagnostic testing.

As a highly selective tumor-specific antigen, Claudin 18.2 has emerged as a second-generation therapeutic target for gastric cancer following HER2, offering new avenues for precision treatment. ANT BIO PTE. LTD. has developed a proprietary Claudin 18.2 diagnostic antibody optimized for IHC applications, featuring exceptional specificity, precise membrane staining, high sensitivity, and comprehensive validation across multiple tumor types.

2. Gastrin

Gastrin is a peptide hormone that regulates gastric acid secretion, pancreatic enzyme release, and gastrointestinal motility. IHC detection of gastrin identifies G-cells in gastric tissue, supporting research on G-cell hyperplasia and gastrinoma diagnosis. This biomarker is essential for studying neuroendocrine tumors of the gastrointestinal tract.

Biomarkers for Colorectal Cancer Diagnosis

1. CDX2

CDX2 is a homeobox transcription factor specifically expressed in the nuclei of intestinal epithelial cells, governing gastrointestinal development and differentiation. As a highly sensitive and specific IHC marker, CDX2 is widely used in surgical pathology to confirm gastrointestinal lineage, particularly for metastatic colorectal cancer diagnosis.

2. MSH6

MSH6 is a vital DNA mismatch repair protein encoded by the MSH6 gene on chromosome 2, forming a functional heterodimer with MSH2. This complex detects DNA base mismatches and insertion/deletion errors, maintaining genomic stability. Germline mutations in MSH6 increase susceptibility to gliomas and hereditary gastrointestinal cancers, making IHC analysis critical for Lynch syndrome screening.

High-Quality IHC Antibody Products

Explore our portfolio of recombinant antibodies, engineered to deliver consistent, reliable results for IHC-based cancer research and diagnosis: